Table 4.
Protection against cardiovascular disease of caffeine, theobromine, and (+)-catechin
| Protection against cardiovascular disease | Caffeine | (+)- Catechin | Theobromine | |
|---|---|---|---|---|
| Peripheral vasodilator | P.a | 0.806 | 0.357 | 0.695 |
| P.i | 0.004 | 0.106 | 0.010 | |
| Antiischemic cerebral | P.a | 0.535 | – | 0.461 |
| P.i | 0.088 | – | 0.133 | |
| Antithrombotic | P.a | 0.428 | 0.234 | 0.319 |
| P.i | 0.044 | 0.162 | 0.090 | |
| Vasoprotector | P.a | 0.391 | 0.652 | 0.309 |
| P.i | 0.082 | 0.014 | 0.147 | |
| Adenosine A1 receptor antagonist | P.a | 0.422 | – | 0.359 |
| P.i | 0.004 | – | 0.005 | |
| Cardiotonic | P.a | 0.551 | – | 0.369 |
| P.i | 0.013 | – | 0.047 | |
| Antihypotensive | P.a | – | 0.217 | 0.277 |
| P.i | – | 0.038 | 0.012 | |
| Thromboxane B2 antagonist | P.a | 0.395 | 0.459 | 0.378 |
| P.i | 0.106 | 0.054 | 0.122 | |
| Antithrombotic | P.a | 0.428 | 0.234 | 0.319 |
| P.i | 0.044 | 0.162 | 0.090 | |
| Platelet adhesion inhibitor | P.a | 0.310 | 0.514 | 0.322 |
| P.i | 0.251 | 0.054 | 0.240 | |
| Treatment of vascular (peripheral) diseases | P.a | 0.225 | 0.440 | 0.190 |
| P.i | 0.091 | 0.010 | 0.137 | |
| Heart failure treatment | P.a | 0.239 | – | 0.129 |
| P.i | 0.025 | – | 0.079 | |
| Anti-hypoxic | P.a | 0.252 | 0.432 | 0.250 |
| P.i | 0.203 | 0.062 | 0.206 | |
| Cardioprotectant | P.a | 0.227 | 0.647 | 0.197 |
| P.i | 0.152 | 0.005 | 0.194 | |
| Nitric oxide synthase stimulant | P.a | – | – | 0.143 |
| P.i | – | – | 0.120 | |
| Cyclic phosphodiesterase amp inhibitor | P.a | 0.943 | 0.266 | 0.858 |
| P.i | 0.003 | 0.134 | 0.003 | |